According to the World Health Organization, more than 1 billion people are at risk of or are affected by neglected tropical diseases. Examples of such diseases include trypanosomiasis, which causes sleeping sickness; leishmaniasis; and Chagas disease, all of which are prevalent in Africa, South America, and India. Our aim within the New Medicines for Trypanosomatidic Infections project was to use (1) synthetic and natural product libraries, (2) screening, and (3) a preclinical absorption, distribution, metabolism, and excretion–toxicity (ADME-Tox) profiling platform to identify compounds that can enter the trypanosomatidic drug discovery value chain. The synthetic compound libraries originated from multiple scaffolds with known antiparasitic activity and natural products from the Hypha Discovery MycoDiverse natural products library. Our focus was first to employ target-based screening to identify inhibitors of the protozoan Trypanosoma brucei pteridine reductase 1 (TbPTR1) and second to use a Trypanosoma brucei phenotypic assay that made use of the T. brucei brucei parasite to identify compounds that inhibited cell growth and caused death. Some of the compounds underwent structure-activity relationship expansion and, when appropriate, were evaluated in a preclinical ADME-Tox assay panel. This preclinical platform has led to the identification of lead-like compounds as well as validated hits in the trypanosomatidic drug discovery value chain.

Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform / Moraes, Carolina B.; Witt, Gesa; Kuzikov, Maria; Ellinger, Bernhard; Calogeropoulou, Theodora; Prousis, Kyriakos C.; Mangani, Stefano; Di Pisa, Flavio; Landi, Giacomo; Iacono, Lucia Dello; Pozzi, Cecilia; Freitas-Junior, Lucio H.; dos Santos Pascoalino, Bruno; Bertolacini, Claudia P.; Behrens, Birte; Keminer, Oliver; Leu, Jennifer; Wolf, Markus; Reinshagen, Jeanette; Cordeiro-da-Silva, Anabela; Santarem, Nuno; Venturelli, Alberto; Wrigley, Stephen; Karunakaran, Deepa; Kebede, Bethlehem; Pöhner, Ina; Müller, Wolfgang; Panecka-Hofman, Joanna; Wade, Rebecca C.; Fenske, Martina; Clos, Joachim; Alunda, José María; Corral, María Jesús; Uliassi, Elisa; Bolognesi, Maria Laura; Linciano, Pasquale; Quotadamo, Antonio; Ferrari, Stefania; Santucci, Matteo; Borsari, Chiara; Costi, Maria Paola; Gul, Sheraz. - In: SLAS DISCOVERY. - ISSN 2472-5552. - 24:3(2019), pp. 346-361. [10.1177/2472555218823171]

Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform

Venturelli, Alberto
Membro del Collaboration Group
;
Linciano, Pasquale;Quotadamo, Antonio;Ferrari, Stefania
Conceptualization
;
Santucci, Matteo;Borsari, Chiara
Methodology
;
Costi, Maria Paola;
2019

Abstract

According to the World Health Organization, more than 1 billion people are at risk of or are affected by neglected tropical diseases. Examples of such diseases include trypanosomiasis, which causes sleeping sickness; leishmaniasis; and Chagas disease, all of which are prevalent in Africa, South America, and India. Our aim within the New Medicines for Trypanosomatidic Infections project was to use (1) synthetic and natural product libraries, (2) screening, and (3) a preclinical absorption, distribution, metabolism, and excretion–toxicity (ADME-Tox) profiling platform to identify compounds that can enter the trypanosomatidic drug discovery value chain. The synthetic compound libraries originated from multiple scaffolds with known antiparasitic activity and natural products from the Hypha Discovery MycoDiverse natural products library. Our focus was first to employ target-based screening to identify inhibitors of the protozoan Trypanosoma brucei pteridine reductase 1 (TbPTR1) and second to use a Trypanosoma brucei phenotypic assay that made use of the T. brucei brucei parasite to identify compounds that inhibited cell growth and caused death. Some of the compounds underwent structure-activity relationship expansion and, when appropriate, were evaluated in a preclinical ADME-Tox assay panel. This preclinical platform has led to the identification of lead-like compounds as well as validated hits in the trypanosomatidic drug discovery value chain.
2019
24
3
346
361
Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform / Moraes, Carolina B.; Witt, Gesa; Kuzikov, Maria; Ellinger, Bernhard; Calogeropoulou, Theodora; Prousis, Kyriakos C.; Mangani, Stefano; Di Pisa, Flavio; Landi, Giacomo; Iacono, Lucia Dello; Pozzi, Cecilia; Freitas-Junior, Lucio H.; dos Santos Pascoalino, Bruno; Bertolacini, Claudia P.; Behrens, Birte; Keminer, Oliver; Leu, Jennifer; Wolf, Markus; Reinshagen, Jeanette; Cordeiro-da-Silva, Anabela; Santarem, Nuno; Venturelli, Alberto; Wrigley, Stephen; Karunakaran, Deepa; Kebede, Bethlehem; Pöhner, Ina; Müller, Wolfgang; Panecka-Hofman, Joanna; Wade, Rebecca C.; Fenske, Martina; Clos, Joachim; Alunda, José María; Corral, María Jesús; Uliassi, Elisa; Bolognesi, Maria Laura; Linciano, Pasquale; Quotadamo, Antonio; Ferrari, Stefania; Santucci, Matteo; Borsari, Chiara; Costi, Maria Paola; Gul, Sheraz. - In: SLAS DISCOVERY. - ISSN 2472-5552. - 24:3(2019), pp. 346-361. [10.1177/2472555218823171]
Moraes, Carolina B.; Witt, Gesa; Kuzikov, Maria; Ellinger, Bernhard; Calogeropoulou, Theodora; Prousis, Kyriakos C.; Mangani, Stefano; Di Pisa, Flavio...espandi
File in questo prodotto:
File Dimensione Formato  
Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform.pdf

Open access

Descrizione: Articolo
Tipologia: Versione pubblicata dall'editore
Dimensione 660.65 kB
Formato Adobe PDF
660.65 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1175165
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 21
social impact